TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07577843: A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Janssen Research & Development, LLC · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 460 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT07577843 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07577843 Rescue Dossier →